Novel SPECC1L-MET Fusion Detected in Circulating Tumor DNA in a Patient with Lung Adenocarcinoma following Treatment with Erlotinib and Osimertinib

TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib

Translational Oncology ◽

10.1016/j.tranon.2021.101163 ◽

2021 ◽

Vol 14 (9) ◽

pp. 101163

Author(s):

Ruofei Yu ◽

Hua Bai ◽

Tangai Li ◽

Bingyu Gao ◽

Jiefei Han ◽

...

Keyword(s):

Epidermal Growth Factor Receptor ◽

Growth Factor ◽

Epidermal Growth Factor ◽

Lung Adenocarcinoma ◽

Growth Factor Receptor ◽

Circulating Tumor Dna ◽

Tp53 Mutations ◽

Epidermal Growth ◽

Receptor Mutant ◽

Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients

Lung Cancer ◽

10.1016/j.lungcan.2020.06.009 ◽

2020 ◽

Vol 146 ◽

pp. 327-334 ◽

Cited By ~ 2

Author(s):

Weixiong Yang ◽

Na You ◽

Minghan Jia ◽

Sai-Ching Jim Yeung ◽

Wei Ou ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Circulating Tumor Dna ◽

Low Risk ◽

Stage I ◽

Risk Of Recurrence ◽

Pathologic Stage ◽

P2.09-03 Prognostic Value of Mutated KRAS in Circulating Tumor DNA Prior to Therapy in Patients with Lung Adenocarcinoma

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2019.08.1652 ◽

2019 ◽

Vol 14 (10) ◽

pp. S769

Author(s):

S.G.F. Wahl ◽

H.Y. Dai ◽

E.F. Emdal ◽

A.L. Ottestad ◽

E. Richardsen ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Prognostic Value ◽

Circulating Tumor Dna ◽

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2017.04.023 ◽

2017 ◽

Vol 12 (10) ◽

pp. e155-e157 ◽

Cited By ~ 5

Author(s):

Ibiayi Dagogo-Jack ◽

David Fabrizio ◽

Jochen Lennerz ◽

Alexa B. Schrock ◽

Lauren Young ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Circulating Tumor Dna ◽

Mechanism Of Resistance ◽

Non-Invasive Monitoring of Urinary KRAS Circulating Tumor DNA for Treatment Response and Minimal Residual Disease in Patients with Lung Adenocarcinoma.

10.1200/jco.2015.33.15_suppl.e19092 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e19092-e19092 ◽

Cited By ~ 1

Author(s):

James Michael Randall ◽

Mark G. Erlander ◽

Cecile Rose T. Vibat ◽

Saege Hancock ◽

Vlada Melnikova ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Treatment Response ◽

Minimal Residual Disease ◽

Residual Disease ◽

Circulating Tumor Dna ◽

Invasive Monitoring ◽

Non Invasive ◽

Tumor Dna ◽

Minimal Residual

Circulating tumor DNA sequencing to reveal the genomic complexity of advanced EGFR-mutant lung adenocarcinoma.

10.1200/jco.2016.34.15_suppl.e23079 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e23079-e23079

Author(s):

Collin M. Blakely ◽

Kimberly C. Banks ◽

Richard Burnham Lanman ◽

Jonathan Riess ◽

Philip C. Mack ◽

...

Keyword(s):

Dna Sequencing ◽

Lung Adenocarcinoma ◽

Circulating Tumor Dna ◽

Genomic Complexity ◽

Egfr Mutant ◽

Mutation count, a potential surrogate for tumor mutation load, of circulating tumor DNA (ctDNA) using targeted panel sequencing correlates with clinical outcomes in late stage lung adenocarcinoma and small cell lung cancer.

10.1200/jco.2018.36.15_suppl.12045 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 12045-12045

Author(s):

Stephanie Yaung ◽

Liu Xi ◽

Corinna Woestmann ◽

Sylvie McNamara ◽

Bernd Hinzmann ◽

...

Keyword(s):

Lung Cancer ◽

Lung Adenocarcinoma ◽

Small Cell Lung Cancer ◽

Late Stage ◽

Circulating Tumor Dna ◽

Small Cell ◽

Mutation Load ◽

Small Cell Lung ◽

Tumor Dna ◽

Panel Sequencing

3136 Kinetic monitoring of EGFR and KRAS mutations in urinary circulating tumor DNA predicts radiographic progression and response in patients with metastatic lung adenocarcinoma

European Journal of Cancer ◽

10.1016/s0959-8049(16)31777-4 ◽

2015 ◽

Vol 51 ◽

pp. S648-S649

Author(s):

H. Husain ◽

V. Melnikova ◽

K. Kosco ◽

S. Hancock ◽

E. Samuelsz ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Radiographic Progression ◽

Circulating Tumor Dna ◽

Kras Mutations ◽

Metastatic Lung ◽

Erratum to: Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors

Molecular Oncology ◽

10.1002/1878-0261.13139 ◽

2022 ◽

Vol 16 (1) ◽

pp. 310-310

Keyword(s):

Lung Adenocarcinoma ◽

Early Treatment ◽

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors ◽

Circulating Tumor Dna ◽

Treatment Responses ◽

Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma.

10.1200/jco.2015.33.15_suppl.8081 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 8081-8081 ◽

Cited By ~ 6

Author(s):

Hatim Husain ◽

Karena Kosco ◽

Cecile Rose T. Vibat ◽

Vlada Melnikova ◽

Mark G. Erlander ◽

...

Keyword(s):

Lung Adenocarcinoma ◽

Radiographic Progression ◽

Circulating Tumor Dna ◽

Metastatic Lung ◽

Tumor Dna ◽

Egfr T790m